Un nuevo estudio demuestra que el lecanemab retrasa la progresión de la enfermedad en su fase inicial. Pero los efectos secundarios son relevantes.
- Post Doctoral Research Assistant, University of Bradford
Lecanemab slows progression of early-stage Alzheimer’s disease in some, new study shows. But the ‘adverse events’ are significant.
Contact Stuart for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Website
- Article Feed
- ORCID
- Joined
